Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 92 clinical trials
ProBio: A Biomarker Driven Study in Patients With Metastatic Castrate Resistant Prostate Cancer (ProBio)

Metastatic castrate resistant prostate cancer (mCRPC) is an advanced form of prostate cancer and it is estimated that around 20-30% of all prostate cancer diagnoses will develop mCRPC at some point in their disease trajectory. The last years, new drugs have been approved for treatment of mCRPC. Although the drugs …

  • 2 views
  • 10 Feb, 2022
  • 19 locations
Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type (TRAHD)

Recent preclinical studies suggest that combining MEK and MDM2 inhibition synergize to induce apoptosis in RAS/BRAF-mutant and TP53 wild-type CRC models. In vitro, in RKO cell lines (poorly

TP53
renal function test
ki-ras
g-csf
neutrophil count
  • 19 views
  • 27 Feb, 2022
  • 1 location
Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT

Recent studies have demonstrated that allogeneic hematopoietic stem cell transplantation (allo-HSCT) could be a valuable treatment choice for TP53+ myeloid tumors, such as acute myeloid leukemia

  • 0 views
  • 23 Jan, 2021
  • 1 location
Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer

A prospective, multi-center, phase II study of 21 patients to evaluate the efficacy of the EGFR inhibitor, Cetuximab in patients with mCRC harboring APC, TP53 and RAS mutations.

  • 0 views
  • 13 May, 2022
  • 2 locations
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

This phase II trial studies the how well berzosertib and irinotecan work in treating patients with gastric or gastroesophageal junction cancer that is growing, spreading or getting worse (progressive), has spread to other places in the body (metastatic), or cannot be removed by surgery (unresectable). Berzosertib may stop the growth …

  • 0 views
  • 16 Jun, 2022
  • 14 locations
Screening With Whole Body MRI For Detection Of Primary Tumors In Children And Adults With Li-Fraumeni Syndrome (LFS) And Other Cancer Predisposition Syndromes

This study is evaluating Whole Body MRI as a possible screening tool to diagnose cancer for people with LFS and other inherited cancer predisposition syndromes.

  • 20 views
  • 21 Mar, 2022
  • 2 locations
The p53 Breast Cancer Trial (p53b)

This is a multicenter, open labeled, phase 2 clinical trial, where patients are stratified to one of two treatment groups based on upfront TP53 mutation status; i.e. TP53 mutated vs. TP53 wt

  • 28 views
  • 24 Feb, 2022
  • 4 locations
Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53

Study ASTX295-01 is a first in human Phase 1/2 open-label study of the safety, pharmacokinetics, and preliminary activity of ASTX295 in subjects with wild-type TP53 advanced solid tumors. Phase

TP53
metastasis
neutrophil count
liver metastasis
glomerular filtration rate
  • 5 views
  • 26 Mar, 2022
  • 7 locations
Milademetan in Advanced/Metastatic Solid Tumors

intolerant to standard-of-care therapy that exhibit wild-type (WT) TP53 and MDM2 copy number (CN) ≥ 12 using prespecified biomarker criteria.

  • 0 views
  • 09 Apr, 2022
  • 8 locations
A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer

This a phase II and III study whose purpose is to compare how long various treatment regimens can keep the cancer from worsening or coming back in people with serous or p53 abnormal endometrial cancer. The study is divided into three cohorts: Early stage cohort, advanced stage cohort, and exploratory …

carcinoma
TP53
endometrial carcinoma
carboplatin
cancer
  • 0 views
  • 02 Jun, 2021
  • 1 location